Sign inJoin waitlistJoin the waitlist

RB

Reva Basho

Physician · Providence Southern California

Credentials: · · · · · ·

History

Providence Southern California
2023–Present

University of Texas M D Anderson Cancer Center
2014–2017
Internal Medicine
University of California-Los Angeles
2011–2014
Baylor College of Medicine
2006–2010

Research

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal…
JAMA Oncology · 2017 · First of 20 authors · 163 citations
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer
Cancer Cell · 2024 · 150 citations
COVID-19 in cancer patients: risk, clinical features, and management
Review · Cancer Biology and Medicine · 2020 · 147 citations

Heather McArthur
7 papers
Jennifer Litton
5 papers
Funda Meric-Bernstam
4 papers
SM
Stacy Moulder
4 papers
Vicente Valero
4 papers
Alice Chung
3 papers
Armando Giuliano
3 papers
FJ
Filip Janku
3 papers
Mariana Mac Gregor
3 papers
Naoto Ueno
3 papers
Philomena McAndrew
3 papers
Stephen Shiao
3 papers

Clinical trials

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2023–2027
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
Principal investigator · Withdrawn · Phase 1, Phase 2
Reva Basho
2022–2024
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Eli Lilly and Company
2023–2030
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030